Critical Comparison: Oculis (NASDAQ:OCS) versus Immunome (NASDAQ:IMNM)

Oculis (NASDAQ:OCS) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Volatility & Risk

Oculis has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.

Profitability

This table compares Oculis and Immunome’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oculis	-8,043.28%	-71.31%	-56.85%
Immunome	-3,014.59%	-48.63%	-41.62%

Institutional and Insider Ownership

22.3% of Oculis shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 8.6% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Oculis and Immunome, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	0	0	5	0	3.00
Immunome	0	0	7	0	3.00

Oculis presently has a consensus target price of $28.80, indicating a potential upside of 54.01%. Immunome has a consensus target price of $28.83, indicating a potential upside of 170.48%. Given Immunome’s higher probable upside, analysts plainly believe Immunome is more favorable than Oculis.

Valuation and Earnings

This table compares Oculis and Immunome”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$980,000.00	772.88	-$98.92 million	($1.93)	-9.69
Immunome	$10.13 million	65.69	-$106.81 million	($8.11)	-1.31

Oculis has higher earnings, but lower revenue than Immunome. Oculis is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Summary

Immunome beats Oculis on 10 of the 13 factors compared between the two stocks.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.